TLC BioSciences Corp
TTPEX:7924371.50
TWD
-30.00
(-7.47%)
TLC BioSciences Corp
TPEX:7924
(Taipei Exchange)
Recent
price
371.50
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- TLC BioSciences Corp is a clinical-stage specialty pharmaceutical company that engages in the research, development, and commercialization of lipid-based drug delivery systems and nanomedicines. The company focuses on developing therapeutics targeting osteoarthritis pain, ophthalmology, oncology, and infectious diseases through proprietary drug formulation platforms. TLC BioSciences organizes its pipeline and offerings into distinct technology platforms and pharmaceutical product candidates, which include BioSeizer, a proprietary lipid-based technology designed to achieve sustained, localized release of therapeutic agents over extended periods; NanoX, an active-loading nanomedicine platform that improves drug pharmacokinetics and targeted biodistribution while reducing systemic toxicity; TLC599, a BioSeizer-enabled sustained-release liposomal formulation of dexamethasone sodium phosphate developed to provide prolonged pain relief for patients suffering from knee osteoarthritis; TLC399 (ProDex), a sustained-release intravitreal injection of dexamethasone formulated to treat macular edema associated with retinal vein occlusion and other retinal diseases; TLC590, a non-opioid BioSeizer-formulated liposomal ropivacaine designed for post-surgical local analgesia; TLC178, a NanoX-formulated liposomal vinorelbine indicated for advanced soft tissue sarcomas and pediatric rhabdomyosarcoma; TLC198, a liposomal formulation of docetaxel for solid tumor malignancies; and specialty commercial therapeutics including liposomal doxorubicin (Lipo-Dox) for oncologic indications and liposomal amphotericin B for severe systemic fungal infections. TLC BioSciences Corp operates internationally, maintaining corporate, clinical, and scientific operations across Taiwan, the United States, Japan, and the Netherlands. The company was founded in 1997 and is headquartered in Taipei, Taiwan. In recent developments, TLC BioSciences Corp completed a corporate reorganization to optimize its capital structure and registered its shares on the Taipei Exchange Emerging Stock Market under ticker 7924. The company has advanced its clinical and commercial strategy through an exclusive licensing and distribution agreement with Seikagaku Corporation for the commercialization of TLC599 across key international markets including the United States and Japan, completed pivotal Phase III clinical evaluation for TLC599 in knee osteoarthritis, expanded strategic manufacturing and supply collaborations for its BioSeizer and NanoX product lines, and broadened its clinical pipeline into pediatric rare disease oncology and sustained-release ophthalmic indications.